ClinicalTrials.gg
CompletedNCT02953652Updated Sep 19, 2024Results posted

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

A Phase 2 interventional study of HBI-8000 in Peripheral T-Cell Lymphoma (PTCL), sponsored by HUYABIO International, LLC.. Completed at 23 sites in 2 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by HUYABIO International, LLC. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.

Enrollment
11th of 29
55 · median 44
Started
2016
with 3 others
Phase 2
16 of 29
8 open now
Registered
5th of 29
by date
Lead sponsor
1 of 29
HUYABIO International, LLC.

Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 11th largest by enrollment, is one of 4 that started in 2016, is one of 16 in phase 2, and was the 5th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).

Read the detailed description

This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL). HBI 8000 will be administered orally approximately 30 minutes after any regular meal twice a week. There will be 3-4 days between dosing. A cycle is defined as consecutive 28 days. HBI-8000 administration will be continued until disease progression or unacceptable toxicities are observed despite appropriate dose reduction or treatment interruption.

03

Conditions studied

  • Peripheral T-Cell Lymphoma (PTCL)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological diagnosis of the following peripheral T-cell lymphoma (PTCL) subtypes as defined by the WHO classification (2008) may be included:

    1. PTCL, NOS
    2. Angioimmunoblastic T-cell lymphoma (AITL)
    3. Anaplastic large-cell lymphoma (ALCL), ALK+
    4. Anaplastic large-cell lymphoma (ALCL), ALK-
    5. Enteropathy-associated T-cell lymphoma (EATL)
    6. Hepatosplenic T-cell lymphoma
    7. Subcutaneous panniculitis-like T-cell lymphoma
  2. Patients for whom at least 1 is confirmed by the lesion assessment at baseline; an evaluable lesion is defined as more than 1.5 cm in greatest dimension and can be followed by imaging.
  3. disease after receiving ≥1 prior systemic therapy with antitumor agent(s) and there is no other available treatment which can be considered appropriate for patients. Systemic therapy is defined as frontline chemotherapy or immunotherapy administered systemically.
  4. Male or female, age 20 years or older
  5. Performance Status of 0-2
  6. of greater than 3 months
  7. Meeting the following laboratory criteria for screening:

    1. >1500/µL independent of growth factor support within 7 days of starting the study drug
    2. >75,000/µL independent of transfusion within 14 days of starting the study drug
    3. >8 g/dL independent of transfusion within 14 days of starting the study drug
    4. Serum creatinine \< 1.5 X
    5. Serum /glutamyl oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamyl pyruvic transaminase (ALT/SGPT) less than or equal to 3 X ULN
    6. Serum less than or equal to 1.5 X ULN
  8. Negative serum pregnancy test for females of childbearing (reproductive) potential. Female patients of child bearing potential must use an effective method of (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) during treatment period and 1 month thereafter. Males must use an effective method of birth control (2 barrier methods) during treatment period and 3 months thereafter.

    Note: Female patients will be considered to be women of unless having undergone permanent contraception or . Postmenopausal is defined as at least 12 months without menses with no other medical reasons (e.g., chemical menopause because of treatment with anti-malignant tumor agents)

  9. Signed

Exclusion criteria

Exclusion Criteria:

  1. Patients in whom central nervous system lymphoma is recognized during screening (if suspected clinically, imaging study should be performed to confirm)
  2. Male patients with > 450 msec at screening, female patients with QTcF > 470 msec at screening or patients with congenital long QT syndrome, arrhythmia, history of congestive heart failure ( Class III or IV) or acute myocardial infarction within 6 months of starting the study drug
  3. Patients with known to benzamide class of compounds or any of the components of HBI-8000 tablets, and patients with prior exposure of HBI-8000
  4. Patients with a history of second other than disease under study. The exceptions are disease that has been treated with curative intent with no evidence of recurrence in past 2 years including:

    1. Basal cell carcinoma of the skin
    2. Squamous cell carcinoma of the skin
    3. Cervical carcinoma in situ
    4. Carcinoma in situ of the breast
    5. An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
    6. Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
    7. Thyroid cancer with differentiated histology (e.g. papillary) treated with curative intent
  5. stem cell transplantation within 12 weeks (84 days) of starting the study drug
  6. History of allogeneic stem cell transplantation
  7. Organ transplantation recipients except autologous hematopoietic stem cell transplantation
  8. Uncontrolled inter-current infection
  9. surface antigen-positive, or virus antibody positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B virus DNA test (real-time PCR measurement) should be performed and if positive, the patient should be excluded from study
  10. Any history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  11. Uncontrolled diabetes mellitus, hypertension, endocrine disorder, bleeding disorder
  12. Major surgery or radiation therapy within 28 days of starting the study drug
  13. Receiving agents or anti-cancer therapy, within 28 days, nitrosourea or mitomycin C within 42 days of starting the study drug
  14. Receiving antibody therapy for PTCL within 12 weeks of starting the study drug
  15. Women who are breastfeeding or women who are not willing to stop breastfeeding during study treatment period and for 30 days after the last dose of study drug
  16. Potential for non-compliance or at increased risk based on investigator's judgement
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    HBI-8000

    Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.

    Drug: HBI-8000

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a complete response (CR) or a partial response (PR) according to International Workshop Response Criteria (IWC) 2014 criteria and assessed by an Independent Overall Efficacy Review Committee (IOERC). CR: Target nodes/nodal masses must regress to \<1.5 cm in longest transverse diameter of a lesion (LDi), no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no bone marrow (BM) involvement. PR: ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \>50% in length beyond normal, no new lesions.

    Time frame: Up to approximately 47 months.

Secondary outcomes

  1. Objective Response Rate by Disease Subtype

    Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a CR or a PR according to IWC 2014 criteria and assessed by an IOERC. CR: Target nodes/nodal masses must regress to \<1.5 cm in LDi, no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no BM involvement. PR: ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \>50% in length beyond normal, no new lesions. Disease subtype (PTCL-NOS, AITL, ALCL, ALK, EATL) was assessed by Central Pathology Review (CPR).

    Time frame: Up to approximately 47 months.

  2. Median Duration of Progression-free Survival (PFS)

    PFS was defined as the duration from the date of the first study drug dose to the disease progression or death, whichever occurs first. PD was defined using the IWC 2014 criteria, as any new lesion or an individual node/lesion must be abnormal with: "LDi \>1.5 cm" and "increase by 50% from perpendicular diameters nadir" and "an increase in LDi or shortest axis perpendicular to the LDi from nadir, 0.5 cm for lesions \<2 cm or 1.0 cm for lesions \>2 cm".

    Time frame: Up to approximately 47 months.

  3. Median Duration of Response (DOR)

    DOR was defined as the duration of response from first response (CR/PR) to disease progression or death, whichever occurs first. CR or PR according to the IWC 2014 criteria was assessed by an IOERC.

    Time frame: Up to approximately 47 months.

  4. Safety Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0

    Safety evaluated as number of participants with treatment-related adverse events as assessed by CTCAE v4.0. From date of first study drug to 30±3 days after the last dosing of the study drug or before the initiation of new cancer treatment.

    Time frame: Up to approximately 44 months.

Other outcomes

  1. Median Duration of Overall Survival (OS)

    Overall survival is defined as the duration from the first dose of study medication to death from any cause.

    Time frame: Up to approximately 55 months.

  2. Pharmacokinetics (Cmax-selected Sites)

    Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the C1D1 and C2D1 doses.

    Time frame: 0 (predose) up to 72 hours postdose on C1D1 and 0 (predose) up to 4 hours postdose on C2D1

  3. Pharmacokinetics AUC (0-INF)

    Area under the plasma concentration time curve from zero (predose) extrapolated to infinity (ng\*h/mL) (Day 1 only), calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration (Clast) divided by the apparent terminal rate constant (λz): AUC(0-last) + Clast/λz. Calculated for the C1D1 dose only.

    Time frame: 0 (predose) up to 72 hours postdose on C1D1

  4. Pharmacokinetics AUC (0-tau)

    Area under the plasma concentration time curve over the dosing interval tau (ng\*h/mL), calculated by linear up/log down trapezoidal summation. Calculated for the C1D1 dose only. Actual elapsed sampling time at tau and the corresponding plasma concentration was used in the calculation of this parameter. If concentrations fall to BLQ before or at tau, AUCall (area under the plasma concentration time curve from zero \[predose\] to the time of the last observation within the dosing interval, calculated by linear up/log down trapezoidal summation) was used as the estimate of this parameter.

    Time frame: 0 (predose) up to 72 hours postdose on C1D1

  5. t 1/2

    Apparent terminal half-life (h), calculated as (ln 2)/λz. Calculated for the C1D1 dose only.

    Time frame: 0 (predose) up to 72 hours postdose on C1D1

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneHBI-8000
Started55
Completed3
Not completed52
Withdrew: Adverse event18
Withdrew: Withdrawal by subject6
Withdrew: Protocol violation1
Withdrew: Disease progression27

Outcome measures

PrimaryObjective Response Rate

Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a complete response (CR) or a partial response (PR) according to International Workshop Response Criteria (IWC) 2014 criteria and assessed by an Independent Overall Efficacy Review Committee (IOERC). CR: Target nodes/nodal masses must regress to \<1.5 cm in longest transverse diameter of a lesion (LDi), no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no bone marrow (BM) involvement. PR: ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \>50% in length beyond normal, no new lesions.

Time frame:
Up to approximately 47 months.
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsHBI-8000
Objective Response Rate21
SecondaryObjective Response Rate by Disease Subtype

Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a CR or a PR according to IWC 2014 criteria and assessed by an IOERC. CR: Target nodes/nodal masses must regress to \<1.5 cm in LDi, no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no BM involvement. PR: ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \>50% in length beyond normal, no new lesions. Disease subtype (PTCL-NOS, AITL, ALCL, ALK, EATL) was assessed by Central Pathology Review (CPR).

Time frame:
Up to approximately 47 months.
Reported as:
Count of participants · Participants
Objective Response Rate by Disease Subtype
ParticipantsPTCL-NOSAITLALCL, ALK-EATL
Objective Response Rate by Disease Subtype12711
SecondaryMedian Duration of Progression-free Survival (PFS)

PFS was defined as the duration from the date of the first study drug dose to the disease progression or death, whichever occurs first. PD was defined using the IWC 2014 criteria, as any new lesion or an individual node/lesion must be abnormal with: "LDi \>1.5 cm" and "increase by 50% from perpendicular diameters nadir" and "an increase in LDi or shortest axis perpendicular to the LDi from nadir, 0.5 cm for lesions \<2 cm or 1.0 cm for lesions \>2 cm".

Time frame:
Up to approximately 47 months.
Reported as:
Median · Months
Median Duration of Progression-free Survival (PFS)
MonthsHBI-8000
Median Duration of Progression-free Survival (PFS)5.5 (2.9 to 24.0)
SecondaryMedian Duration of Response (DOR)

DOR was defined as the duration of response from first response (CR/PR) to disease progression or death, whichever occurs first. CR or PR according to the IWC 2014 criteria was assessed by an IOERC.

Time frame:
Up to approximately 47 months.
Reported as:
Median · Months
Median Duration of Response (DOR)
MonthsHBI-8000
Median Duration of Response (DOR)25.7 (5.4 to NA)
SecondarySafety Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0

Safety evaluated as number of participants with treatment-related adverse events as assessed by CTCAE v4.0. From date of first study drug to 30±3 days after the last dosing of the study drug or before the initiation of new cancer treatment.

Time frame:
Up to approximately 44 months.
Reported as:
Count of participants · Participants
Safety Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0
ParticipantsHBI-8000
Safety Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.051
Other pre-specifiedMedian Duration of Overall Survival (OS)

Overall survival is defined as the duration from the first dose of study medication to death from any cause.

Time frame:
Up to approximately 55 months.
Reported as:
Median · Months
Median Duration of Overall Survival (OS)
MonthsHBI-8000
Median Duration of Overall Survival (OS)33.6 (16.5 to NA)
Other pre-specifiedPharmacokinetics (Cmax-selected Sites)

Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the C1D1 and C2D1 doses.

Time frame:
0 (predose) up to 72 hours postdose on C1D1 and 0 (predose) up to 4 hours postdose on C2D1
Reported as:
Median · ng/mL
Pharmacokinetics (Cmax-selected Sites)
ng/mLC1D1C2D1
Pharmacokinetics (Cmax-selected Sites)220 (71.9 to 650)254 (118 to 483)
Other pre-specifiedPharmacokinetics AUC (0-INF)

Area under the plasma concentration time curve from zero (predose) extrapolated to infinity (ng\*h/mL) (Day 1 only), calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration (Clast) divided by the apparent terminal rate constant (λz): AUC(0-last) + Clast/λz. Calculated for the C1D1 dose only.

Time frame:
0 (predose) up to 72 hours postdose on C1D1
Reported as:
Median · ng*h/mL
Pharmacokinetics AUC (0-INF)
ng*h/mLC1D1
Pharmacokinetics AUC (0-INF)5330 (2230 to 9110)
Other pre-specifiedPharmacokinetics AUC (0-tau)

Area under the plasma concentration time curve over the dosing interval tau (ng\*h/mL), calculated by linear up/log down trapezoidal summation. Calculated for the C1D1 dose only. Actual elapsed sampling time at tau and the corresponding plasma concentration was used in the calculation of this parameter. If concentrations fall to BLQ before or at tau, AUCall (area under the plasma concentration time curve from zero \[predose\] to the time of the last observation within the dosing interval, calculated by linear up/log down trapezoidal summation) was used as the estimate of this parameter.

Time frame:
0 (predose) up to 72 hours postdose on C1D1
Reported as:
Median · ng*h/mL
Pharmacokinetics AUC (0-tau)
ng*h/mLC1D1
Pharmacokinetics AUC (0-tau)4740 (2130 to 8630)
Other pre-specifiedt 1/2

Apparent terminal half-life (h), calculated as (ln 2)/λz. Calculated for the C1D1 dose only.

Time frame:
0 (predose) up to 72 hours postdose on C1D1
Reported as:
Median · hour
t 1/2
hourC1D1
t 1/217.7 (14.3 to 25.5)

Adverse events

Collected over From date of the first study drug to 30 ± 3 days after the last dosing of the study drug or before the initiation of new cancer treatment, an average of around 7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HBI-80001/55 (1.8%)15/55 (27.3%)55/55 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventHBI-8000
Febrile neutropeniaBlood and lymphatic system disorders2/55
Pneumocystis jirovecii pneumoniaInfections and infestations2/55
Aplastic anaemiaBlood and lymphatic system disorders1/55
Angina unstableCardiac disorders1/55
FatigueGeneral disorders1/55
PyrexiaGeneral disorders1/55
PharyngitisInfections and infestations1/55
PneumoniaInfections and infestations1/55
C-reactive protein increasedInvestigations1/55
HyponatraemiaMetabolism and nutrition disorders1/55
Most frequent other events
Showing 10 of 48
Most frequent other events
EventHBI-8000
Platelet count decreasedInvestigations31/55
Neutrophil count decreasedInvestigations21/55
AnaemiaBlood and lymphatic system disorders19/55
DiarrhoeaGastrointestinal disorders19/55
White blood cell count decreasedInvestigations19/55
ThrombocytopeniaBlood and lymphatic system disorders16/55
Decreased appetiteMetabolism and nutrition disorders14/55
PyrexiaGeneral disorders13/55
NauseaGastrointestinal disorders12/55
Lymphocyte count decreasedInvestigations12/55

Baseline characteristics

All subjects who received at least one dose of HBI-8000.

Age, Categorical
Age, Categorical(Participants)HBI-8000
<=18 years0
Between 18 and 65 years15
>=65 years40
Sex: Female, Male
Sex: Female, Male(Participants)HBI-8000
Female20
Male35
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HBI-8000
American Indian or Alaska Native0
Asian55
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)HBI-8000
South Korea16
Japan39
08

Study locations

23 sites
  • Akita, Japan
  • Bunkyōku, Japan
  • Chūōku, Japan
  • Fukuoka, Japan
  • Isehara, Japan
  • Kagoshima, Japan
  • Kobe, Japan
  • Kotoku, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Maebashi, Japan
  • Nagoya, Japan
  • Okayama, Japan
  • Osakasayama, Japan
  • Sapporo, Japan
  • Suita, Japan
  • Yamagata, Japan
  • Ōmura, Japan
  • Busan, Korea, Republic of
  • Goyang-si, Korea, Republic of
  • Incheon, Korea, Republic of
  • Seongnam-si, Korea, Republic of
  • Seoul, Korea, Republic of
09

References and documents

Publications

  • Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. PubMed 36200417 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Feb 2022 and a completion of Feb 2022. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2024, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 3, 2016
Start
Nov 2016
Primary completionActual
Feb 17, 2022
CompletionActual
Feb 17, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02953652
Lead sponsor
HUYABIO International, LLC.
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Nov 2016
Primary completion
Feb 17, 2022
Completion
Feb 17, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Gloria Lee, MD
study chair · HUYABIO International, LLC.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion